98 related articles for article (PubMed ID: 20465622)
1. Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.
Habib N; Salaro C; Al-Ghaithi K; Phelps RG; Saggar S; Cohen SR
Int J Dermatol; 2010 Jan; 49(1):91-4. PubMed ID: 20465622
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor-associated dermatologic and mucosal problems.
Campistol JM; de Fijter JW; Flechner SM; Langone A; Morelon E; Stockfleth E
Clin Transplant; 2010; 24(2):149-56. PubMed ID: 20236129
[TBL] [Abstract][Full Text] [Related]
3. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.
Sonis S; Treister N; Chawla S; Demetri G; Haluska F
Cancer; 2010 Jan; 116(1):210-5. PubMed ID: 19862817
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus-induced aphthous ulcers which disappeared with conversion to everolimus.
Ram R; Swarnalatha G; Neela P; Dakshinamurty KV
Saudi J Kidney Dis Transpl; 2008 Sep; 19(5):819-20. PubMed ID: 18711306
[No Abstract] [Full Text] [Related]
5. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
6. Reversible severe synovitis associated with everolimus.
Kato TS; Sasaoka T; Wada K; Nakatani T; Komamura K
J Heart Lung Transplant; 2010 Jun; 29(6):710-1. PubMed ID: 20188596
[No Abstract] [Full Text] [Related]
7. [Minimize kidney failure in transplantation patients with proliferation signal inhibitors].
Glowacki F; Dharancy S; Noël C; Hazzan M
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S253-6. PubMed ID: 20004331
[TBL] [Abstract][Full Text] [Related]
8. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
9. [Side effects of proliferation signal inhibitors and their management].
Epailly E; Lorho R
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S268-74. PubMed ID: 20004334
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation.
Paramesh AS; Grosskreutz C; Florman SS; Gondolesi GE; Sharma S; Kaufman SS; Fishbein TM
Transplantation; 2004 Jan; 77(1):129-31. PubMed ID: 14724447
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
12. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
13. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
14. [Indications of mTOR inhibitors in liver transplantation].
Calmus Y; Dharancy S
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S245-6. PubMed ID: 20004329
[No Abstract] [Full Text] [Related]
15. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
Lang UE; Heger J; Willbring M; Domula M; Matschke K; Tugtekin SM
Transplant Proc; 2009 Dec; 41(10):4285-8. PubMed ID: 20005385
[TBL] [Abstract][Full Text] [Related]
16. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
Casas-Melley AT; Falkenstein KP; Flynn LM; Ziegler VL; Dunn SP
Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
[TBL] [Abstract][Full Text] [Related]
17. Replacing calcineurin inhibitors with mTOR inhibitors in children.
Sindhi R; Seward J; Mazariegos G; Soltys K; Seward L; Smith A; Kosmach B; Venkataramanan R
Pediatr Transplant; 2005 Jun; 9(3):391-7. PubMed ID: 15910398
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
19. Common occurrence of everolimus-associated aphthous stomatitis in Japanese heart transplant recipients.
Sasaoka T; Kato TS; Oda N; Wada K; Komamura K; Asakura M; Hashimura K; Ishibashi-Ueda H; Nakatani T; Isobe M; Kitakaze M
Transplant Proc; 2010 Nov; 42(9):3700-3. PubMed ID: 21094841
[TBL] [Abstract][Full Text] [Related]
20. Oral ulcers after a transplant.
Ortega KL; Magalhães MG; Santos PS
Br J Oral Maxillofac Surg; 2010 Jan; 48(1):70. PubMed ID: 19231045
[No Abstract] [Full Text] [Related]
[Next] [New Search]
